Filing Details
- Accession Number:
- 0000884731-16-000077
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-06-15 16:19:24
- Reporting Period:
- 2016-06-13
- Filing Date:
- 2016-06-15
- Accepted Time:
- 2016-06-15 16:19:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 884731 | Ariad Pharmaceuticals Inc | ARIA | Biological Products, (No Disgnostic Substances) (2836) | 223106987 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1264778 | Athanese Lavidas | C/O Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-06-13 | 10,000 | $5.49 | 141,631 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-06-13 | 10,000 | $8.21 | 131,631 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-06-14 | 10,000 | $5.49 | 141,631 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2016-06-14 | 10,000 | $7.39 | 151,631 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-06-14 | 20,000 | $8.14 | 131,631 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-06-15 | 15,000 | $7.39 | 146,631 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2016-06-15 | 25,000 | $6.45 | 171,631 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2016-06-15 | 6,250 | $4.91 | 177,881 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-06-15 | 46,250 | $8.24 | 131,631 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-06-13 | 10,000 | $5.49 | 10,000 | $5.49 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-06-14 | 10,000 | $5.49 | 10,000 | $5.49 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-06-14 | 10,000 | $7.39 | 10,000 | $7.39 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-06-15 | 15,000 | $7.39 | 15,000 | $7.39 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-06-15 | 25,000 | $6.45 | 25,000 | $6.45 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2016-06-15 | 6,250 | $4.91 | 6,250 | $4.91 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 10,000 | 2008-06-28 | 2017-06-28 | No | 4 | M | Direct |
| 0 | 2008-06-28 | 2017-06-28 | No | 4 | M | Direct |
| 15,000 | 2014-03-31 | 2024-01-31 | No | 4 | M | Direct |
| 0 | 2014-03-31 | 2024-01-31 | No | 4 | M | Direct |
| 0 | 2015-03-31 | 2025-01-31 | No | 4 | M | Direct |
| 18,750 | 2016-03-31 | 2026-02-01 | No | 4 | M | Direct |
Footnotes
- The shares were acquired and sold upon exercise of stock options that would have expired on 10/21/2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.13 to $8.155, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.23 to $8.265, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- The stock options were granted on 06/28/2007 and vested in three annual installments commencing on 06/28/2008.
- The stock options would have expired on 10/21/2016 (three months following termination of service as a director), in which event the holder would have lost the right to acquire the shares underlying the options.
- The stock options were granted on 01/31/2014 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2014.
- The stock options were granted on 01/31/2015 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2015.
- The stock options were granted on 02/01/2016 and vest as to one-fourth of the options in quarterly installments commencing on March 31, 2016.
Billionaire Hedge Funds
